GPB Scientific, Inc.

Richmond, VA · CIK 0001614077 · Medtech · Private

Curate Cell Processing System using deterministic lateral displacement microfluidics to enrich leukocytes for CAR-T cell therapy manufacturing

gpbscientific.com →
Grants
$5.4M
6 awards
Sector median: 1
Raised
$41M
9 Form D · Sep 2022
48 months since last filing
Contracts
$164K
2 awards · Health and Human S
#475 of 4531 in medtech
Patents
23
0 granted · 23 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,006,911
Federal grantDepartment of Health and Human Services · Phase II · Microfluidic Processing of Leukocytes for Molecular Diagnostic Testing$1,434,795
Private capital raisedForm D · SEC$110,000
Private capital raisedForm D · SEC$1,372,444
Federal grantDepartment of Health and Human Services · Phase II · Microfluidic Processing of Leukocytes for Molecular Diagnostic Testing$695,269
Private capital raisedForm D · SEC$810,000
Federal grantDepartment of Health and Human Services · Phase II · Microfluidic CAR-T Cell Processing Device$279,969
Private capital raisedForm D · SEC$500,000
Federal grantDepartment of Health and Human Services · Phase II · Microfluidic CAR-T Cell Processing Device$1,837,939
Private capital raisedForm D · SEC$1,500,000
Private capital raisedForm D · SEC$15,500,000
Federal grantDepartment of Health and Human Services · Phase II · Microfluidic CAR-T Cell Processing Device$913,556
Private capital raisedForm D · SEC$17,000,000
Federal grantDepartment of Health and Human Services · Phase II · Regulatory Readiness for a Superior Microfluidic CAR-T Therapy Cell Processing System$250,000
Private capital raisedForm D · SEC$3,600,000
Federal contractDepartment of Health and Human Services · Curate System$140,448
Federal contractDepartment of Health and Human Services · Curate Cassette Kits$23,905
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
472Gold Standard Diagnostics Corp.$167K$2.5M
473CMP Scientific Corp$167K$300K
474IONICSCALE LLC$166K—
475GPB Scientific, Inc.$164K$41M
476iRhythm Technologies, Inc.$163K$59M
477Coalesenz Inc.$163K—
478ProNova Solutions, LLC$161K$40M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Michael GrishamExecutive Officer

Patents

USPTO · 0 granted of 23
  • Prevention Of Platelet Activation And Cell Differentiation During The Processing Of Blood And Blood-related Compositionsapplication
  • Methods For Producing Cell Populations With Increased Nucleic Acid Uptakeapplication
  • Ordered Processing Of Blood Products To Produce Therapeutically Active Cellsapplication
  • Methods For Producing Cell Populations With Increased Nucleic Acid Uptakeapplication
  • Methods For Producing Cell Populations With Increased Nucleic Acid Uptakeapplication
  • Methods For Producing Cell Populations With Increased Nucleic Acid Uptakeapplication
  • Systems And Methods For Particle Separation And Concentrationapplication
  • Methods For Producing Cell Populations With Increased Nucleic Acid Uptakeapplication
  • Systems And Methods For Particle Separation And Concentrationapplication
  • Systems And Methods For Particle Separation And Concentrationapplication
  • Prevention Of Platelet Activation And Cell Differentiation During The Processing Of Blood And Blood-related Compositionsapplication
  • Microfluidic Cartridges For Processing Particles And Cellsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.